1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow M6223: new trials by email Literature Review of M6223 trials Research Report on M6223
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) Avelumab, Sacituzumab Govitecan (SG), M6223 - Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | EMD Serono Research & Development Institute, Inc. | 256 | 2022-08-17 | 2026-09-28 |
| First in Human Study of M6223 M6223, Bintrafusp alfa - Metastatic Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 58 | 2020-07-10 | 2026-05-04 |
Carcinoma, Transitional Cell (1) · Urinary Bladder Neoplasms (1)
EMD Serono Research & Development Institute, Inc. (2)
Canada (2) · United States (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
2023 (1)